Medtronic plc — Form 10-K Summary
Reporting period: Fiscal year ended April 28, 2023, compared with fiscal year ended April 29, 2022. The request metadata says “2022 Q4,” but this filing covers the full fiscal year 2023, not a quarterly period.
Business context
Medtronic is an Ireland-incorporated global medical technology company serving customers in more than 150 countries. Its four reportable segments are Cardiovascular, Medical Surgical, Neuroscience, and Diabetes. The company’s products and services include cardiac and vascular devices, surgical and respiratory technologies, neurological therapies, and diabetes management systems.
Financial performance
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Net sales | $31.227 billion | $31.686 billion | Down 1% |
| Operating profit | $5.485 billion | $5.752 billion | Down 5% |
| Operating margin | 17.6% | 18.2% | Down 0.6 percentage points |
| Net income attributable to Medtronic | $3.758 billion | $5.039 billion | Down 25% |
| Diluted GAAP EPS | $2.82 | $3.73 | Down 24% |
| Diluted non-GAAP EPS | $5.29 | $5.55 | Down 5% |
| Cash from operating activities | $6.039 billion | $7.346 billion | Down $1.307 billion |
| Free cash flow | $4.580 billion | $5.978 billion | Down $1.398 billion |
| Gross debt at year-end | $24.4 billion | $24.1 billion | Up $0.3 billion |
GAAP net income and EPS were materially affected by a $910 million net charge from certain tax adjustments, including a $764 million reserve adjustment related to the Puerto Rico transfer-pricing tax case. The filing’s non-GAAP figures exclude specified adjustments and should be considered supplemental, not a replacement for GAAP results.
Cost of products sold rose to $10.719 billion from $10.145 billion, reflecting inflation, labor and materials costs, freight, supply constraints, and inventory reserves. Research and development expense was $2.696 billion, versus $2.746 billion; selling, general, and administrative expense was $10.415 billion, versus $10.292 billion.
Segments and year-over-year changes
- Cardiovascular: Sales of $11.573 billion, up 1%. Structural Heart & Aortic grew 10%, supported by TAVR; results included a $265 million one-time Edwards Lifesciences intellectual-property payment. Cardiac Rhythm & Heart Failure declined 1% and Coronary & Peripheral Vascular declined 3%.
- Medical Surgical: Sales of $8.433 billion, down 8%, driven by currency, China stapling tenders, lower ventilator demand, and supply challenges. Half of Renal Care Solutions was contributed to Mozarc Medical on April 1, 2023.
- Neuroscience: Sales of $8.959 billion, up 2%, with growth in Specialty Therapies partly offset by flat Cranial & Spinal Technologies and lower Neuromodulation sales.
- Diabetes: Sales of $2.262 billion, down 3%, primarily due to currency and U.S. declines, partly offset by international growth.
Management attributed the overall sales decline mainly to unfavorable currency effects, China volume-based procurement tenders and COVID-19 resurgence, and supply-chain challenges. U.S. sales rose 1%; non-U.S. developed-market sales fell 7%; emerging-market sales were approximately flat.
Cash, debt, liquidity, and capital allocation
- Cash and cash equivalents were $1.543 billion and current investments were $6.416 billion at year-end, totaling about $7.96 billion in these disclosed liquid resources.
- Current liabilities were $9.051 billion; current debt obligations were $20 million. Long-term debt was $24.344 billion.
- The company reported no outstanding commercial paper or borrowings under its $3.5 billion revolving credit facility, which matures in December 2027; it was in compliance with facility covenants.
- Operating cash flow declined as customer collections slowed, inventory spending increased, and cash taxes rose, including a tax-related cash deposit. Capital expenditures were $1.459 billion.
- Dividends paid totaled $3.616 billion. Medtronic repurchased 6 million shares in FY2023 for an average $91.31 per share, with about $2.4 billion remaining under its authorization. The quarterly dividend was raised to $0.69 per share for FY2024 Q1.
Outlook, risks, and unusual items
The filing does not provide a clear quantified full-year FY2024 revenue or earnings guidance figure. Management describes product launches and pipeline opportunities as potential growth drivers, including Micra, TAVR, MiniMed 780G, and new surgical and neurological technologies. It expected to complete the planned separation of Patient Monitoring and Respiratory Interventions 18–24 months after its October 2022 announcement.
- Tax matters: The Puerto Rico tax-court opinion remains subject to appeal; the company recorded the $764 million reserve adjustment and assumed the court’s findings apply to subsequent years. A separate Israeli court decision issued June 1, 2023 was estimated to potentially result in an approximately $200 million tax charge, including interest; the company was evaluating the decision and a possible appeal.
- Legal contingencies: Accrued litigation was approximately $0.3 billion. A jury verdict in Colibri patent litigation was approximately $106 million; Medtronic is appealing and had not accrued an expense because it did not consider a loss probable. The filing also describes pelvic mesh, hernia mesh, and insulin-pump retainer-ring lawsuits, for which loss estimates were not considered probable and reasonably estimable.
- Product and regulatory matters: Medtronic stopped sales of the HVAD system in 2021 but continues patient support. A field corrective action affected the Harmony transcatheter pulmonary valve. The U.S. FDA lifted the Diabetes warning letter in April 2023.
- Business risks: Management highlights competition and pricing pressure, reimbursement and tender changes, currency volatility, inflation and interest rates, supply interruptions, procedure-volume uncertainty, cybersecurity, regulatory requirements, product quality and liability, and geopolitical and trade risks. China represented approximately 7% of revenue; Russia and Ukraine together were less than 1% of revenue and assets in FY2023.
- Other unusual items: FY2023 restructuring and associated costs totaled $647 million. The company recorded $136 million of non-cash pre-tax charges related primarily to the RCS transaction. FY2022 included $881 million of MCS impairment and related costs in the non-GAAP reconciliation.
Management stated that its balance sheet, cash, current investments, credit facility, commercial paper programs, and expected operating cash flows should meet foreseeable operating and contractual needs. The independent auditor gave an unqualified opinion on the financial statements and internal control over financial reporting; the Puerto Rico uncertain-tax-position reserve was identified as a critical audit matter.
Most important facts for investors to verify
- Underlying sales and margin trends after separating currency, China tenders, the $265 million Edwards payment, and divestiture effects.
- Cash conversion and working-capital performance, especially collections and inventory levels, following the FY2023 decline in operating cash flow and free cash flow.
- The outcome and cash consequences of the Puerto Rico tax litigation, the Israeli tax decision, and other uncertain tax positions.
- Progress and costs of the Patient Monitoring/Respiratory Interventions separation and the Mozarc Medical transaction, including contingent payments and retained investment valuation.
- Whether launches and pipeline products deliver the growth management anticipates, while monitoring product corrective actions, regulatory approvals, and litigation exposure.